Table 1 Patient characteristics (n = 27)
Characteristics | Osimertinib (n = 11) % | Osimertinib and bevacizumab (n = 16) % |
|---|---|---|
Age (median) | 47–70 (56) | 46–75 (60) |
Gender | ||
 Female | 4 (36.4) | 8 (50.0) |
 Male | 7 (63.6) | 8 (50.0) |
History of tobacco exposure | ||
 Yes | 6 (54.5) | 7 (43.8) |
 No | 5 (45.5) | 9 (56.2) |
ECOG performance status score | ||
 ≥ 2 | 9 (81.8) | 11 (68.8) |
 < 2 | 2 (18.2) | 5 (31.2) |
EGFR mutation | ||
 Exon 21 L858R | 6 (54.5) (1 T790M) | 8 (50.0) |
 Exon 19 deletion | 5 (45.5) (1 T790M) | 8 (50.0) (1 T790M) |
Neurological symptoms | ||
 Yes | 10 (90.9) | 15 (93.8) |
 No | 1 (9.1) | 1 (6.2) |
Exclusively diagnosed LM by CSF cytology | ||
 Yes | 5 (45.5) | 8 (50.0) |
 No | 6 (54.5) | 8 (50.0) |
Exclusively diagnosed LM by MRI | ||
 Positive | 9 (81.8) | 12 (75.0) |
 Negative | 2 (18.2) | 4 (25.0) |
Both positive for MRI and CSF cytology | ||
 Yes | 5 (45.5) | 5 (31.2) |
 No | 6 (54.5) | 11 (68.8) |
Systemic therapy before LM diagnosis | ||
 First generation TKIs | ||
  Yes | 10 (90.9) | 14 (87.5) |
  No | 1 (9.1) | 2 (12.5) |
 Chemotherapy | ||
  Yes | 1 (9.1) | 3 (18.7) |
  No | 10 (90.9) | 13 (81.3) |
 Brain radiotherapy | ||
  Yes | 2 (18.2) | 2 (12.5) |
  No | 9 (81.8) | 14 (87.5) |
Subsequent treatments after osi ± beva | ||
 Osimertinib + ITC | 1 (9.1) | 3 (18.8) |
 Osimertinib + WBRT | 0 (0.0) | 1 (6.2) |
 Chemotherapy | 2 (18.2) | 1 (6.2) |
 Osimertinib 160 mg | 1 (9.1) | 0 (0.0) |
 Continued prior treatments | 7 (63.6) | 11 (68.8) |